Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs), has shaped therapeutic landscape of some type of cancers...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shuang, Xu, Linping, Yi, Ming, Yu, Shengnan, Wu, Kongming, Luo, Suxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833286/
https://www.ncbi.nlm.nih.gov/pubmed/31690319
http://dx.doi.org/10.1186/s12943-019-1091-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833286/
https://www.ncbi.nlm.nih.gov/pubmed/31690319
http://dx.doi.org/10.1186/s12943-019-1091-2

Ejemplares similares